Mechanism of metastasis suppression by luteolin in breast cancer

Matthew T Cook Department of Biology, Washburn University, Topeka, KS, USA Abstract: Metastatic breast cancer is typically an extremely aggressive cancer with poor prognosis. Metastasis requires the orchestration of homeostatic factors and cellular programs, many of which are potential therapeutic t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Cook MT
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	luteolin metastasis NOTCH β-catenin RTK AKT Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/b1616cfbccc14ac4993b8c385421598c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b1616cfbccc14ac4993b8c385421598c
record_format	dspace
spelling	oai:doaj.org-article:b1616cfbccc14ac4993b8c385421598c2021-12-02T01:17:18ZMechanism of metastasis suppression by luteolin in breast cancer1179-1314https://doaj.org/article/b1616cfbccc14ac4993b8c385421598c2018-06-01T00:00:00Zhttps://www.dovepress.com/mechanism-of-metastasis-suppression-by-luteolin-in-breast-cancer-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Matthew T Cook Department of Biology, Washburn University, Topeka, KS, USA Abstract: Metastatic breast cancer is typically an extremely aggressive cancer with poor prognosis. Metastasis requires the orchestration of homeostatic factors and cellular programs, many of which are potential therapeutic targets. Luteolin (2-[3,4-dihydroxyphenyl]-5,7-dihydroxy-4-chromenone), is a naturally occurring flavonoid found in fruits and vegetables that exhibits many anticancer properties. Luteolin obstructs metastasis through both direct and indirect mechanisms. For instance, luteolin may suppress breast cancer invasion by acting as an antiangiogenic therapeutic inhibiting VEGF production and its receptor’s activity. Furthermore, luteolin decreases epithelial–mesenchymal transition markers and metastatic proclivity. Luteolin also acts as an antiproliferative by suppressing receptor tyrosine-kinase activity and apoptosis, both of which could prevent incipient colonization of breast cancer. Many of these antimetastatic characteristics accredited to luteolin are likely functionally related. For instance, the PI3K/Akt pathway, which is impeded by luteolin, has several downstream programs involved in increased proliferation, survival, and metastatic potential in breast cancer. In this review, luteolin’s ability to ameliorate breast cancer is summarized. The paper also offers insight into the molecular mechanisms by which luteolin may suppress breast cancer metastasis. Keywords: angiogenesis, MMP, NOTCH, β-catenin, RTK, AktCook MTDove Medical PressarticleluteolinmetastasisNOTCHβ-cateninRTKAKTNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 10, Pp 89-100 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	luteolin metastasis NOTCH β-catenin RTK AKT Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	luteolin metastasis NOTCH β-catenin RTK AKT Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Cook MT Mechanism of metastasis suppression by luteolin in breast cancer
description	Matthew T Cook Department of Biology, Washburn University, Topeka, KS, USA Abstract: Metastatic breast cancer is typically an extremely aggressive cancer with poor prognosis. Metastasis requires the orchestration of homeostatic factors and cellular programs, many of which are potential therapeutic targets. Luteolin (2-[3,4-dihydroxyphenyl]-5,7-dihydroxy-4-chromenone), is a naturally occurring flavonoid found in fruits and vegetables that exhibits many anticancer properties. Luteolin obstructs metastasis through both direct and indirect mechanisms. For instance, luteolin may suppress breast cancer invasion by acting as an antiangiogenic therapeutic inhibiting VEGF production and its receptor’s activity. Furthermore, luteolin decreases epithelial–mesenchymal transition markers and metastatic proclivity. Luteolin also acts as an antiproliferative by suppressing receptor tyrosine-kinase activity and apoptosis, both of which could prevent incipient colonization of breast cancer. Many of these antimetastatic characteristics accredited to luteolin are likely functionally related. For instance, the PI3K/Akt pathway, which is impeded by luteolin, has several downstream programs involved in increased proliferation, survival, and metastatic potential in breast cancer. In this review, luteolin’s ability to ameliorate breast cancer is summarized. The paper also offers insight into the molecular mechanisms by which luteolin may suppress breast cancer metastasis. Keywords: angiogenesis, MMP, NOTCH, β-catenin, RTK, Akt
format	article
author	Cook MT
author_facet	Cook MT
author_sort	Cook MT
title	Mechanism of metastasis suppression by luteolin in breast cancer
title_short	Mechanism of metastasis suppression by luteolin in breast cancer
title_full	Mechanism of metastasis suppression by luteolin in breast cancer
title_fullStr	Mechanism of metastasis suppression by luteolin in breast cancer
title_full_unstemmed	Mechanism of metastasis suppression by luteolin in breast cancer
title_sort	mechanism of metastasis suppression by luteolin in breast cancer
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/b1616cfbccc14ac4993b8c385421598c
work_keys_str_mv	AT cookmt mechanismofmetastasissuppressionbyluteolininbreastcancer
_version_	1718403157647687680

Mechanism of metastasis suppression by luteolin in breast cancer

Ejemplares similares